Cadila Clarifies Voluntary Recall Of Drugs In The US Market

Drug maker Cadila Healthcare Limited has clarified that its drugs in the US have been recalled by its US subsidiary, Zydus Pharma USA; it was a class III type recall. The company gave the clarification following a news report that stated that the company had to recall one of its drugs in the US market.

"The recall by our US subsidiary was voluntary and a class-III type recall, which means that the use of the product is not likely to cause any adverse health consequences. There is no material impact”, said the company in a letter to the National Stock Exchange (NSE).

The NSE on December 31, 2014, had sought clarification from the pharma major after a news report suggested that along with Wockhardt and Hospira, Cadila too has voluntarily recalled 58,920 bottles of Benzonatate Capsules—these medicines are used to treat coughs. The US Food and Drug Administration (FDA) had published this information on its website.

Representational Image